2-chloroethyl 2,6-dimethyl-4-(3-nitrophenyl)-5-ethoxy-carbonyl-1,4-dihydropyridine-3-carboxylate | 54585-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloroethyl 2,6-dimethyl-4-(3-nitrophenyl)-5-ethoxy-carbonyl-1,4-dihydropyridine-3-carboxylate
• 英文别名: 2-chloroethyl ethyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylate；2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-chloroethyl ester 5-ethyl ester；5-O-(2-chloroethyl) 3-O-ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 54585-92-1
• 化学式: C₁₉H₂₁ClN₂O₆
• 分子量: 408.839
• InChiKey: PYAZZLMSTSUOEG-UHFFFAOYSA-N

物化性质

• 熔点：
  164-165 °C
• 沸点：
  540.4±50.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-甲基-3,3-二苯基丙胺 、 2-chloroethyl 2,6-dimethyl-4-(3-nitrophenyl)-5-ethoxy-carbonyl-1,4-dihydropyridine-3-carboxylate 以55%的产率得到5-O-[2-[3,3-diphenylpropyl(methyl)amino]ethyl] 3-O-ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

  摘要：

  A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenyl-propylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4-dihydropyridines binding site labelled by H-3-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375-lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80015-9
• 作为产物：
  描述：

  2-乙酰基乙酸氯乙酯 在 盐酸 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 7.0h， 生成 2-chloroethyl 2,6-dimethyl-4-(3-nitrophenyl)-5-ethoxy-carbonyl-1,4-dihydropyridine-3-carboxylate
  参考文献：
  名称：

  Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

  摘要：

  A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenyl-propylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4-dihydropyridines binding site labelled by H-3-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375-lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80015-9

文献信息

• Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them
  申请人：Pierrel S.p.A.

  公开号：EP0097821A2

  公开（公告）日：1984-01-11

  Basic esters of 1,4-dihydropyridine-3,5-dicarboxylic acid of formula (I) are described, in which R' is a linear or branched alkyl radical containing 1-5 carbon atoms which is unsubstituted or substituted by an alkoxy group; R2 is a phenyl or a nitrophenyl radical; R3 is phenyl, phenyl substituted by one to three radicals selected from (C1-4)alkyl, (C1-4)alkoxy, fluoro, chloro, bromo, nitro, cyano, carb(C1-4)alkoxy, trifluoromethyl, hydroxy, amino, mono- or di-alkylamino, mono- or di-acylamino, mercapto, S(O)n-alkyl with n = 0,1 or 2, (C1-C5)acyl, carbamoyl, ureido or R3 is a 5 or 6 membered heteroaryl monocyclic radical which contains one or more heteroatoms which are N, 0 or S such as unsubstituted pyridyl, pirazinyl, pyrimidyl, furyl, imidazolyl, thienyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl or mono-, di- or tri-substituted with alkyl, alkoxy, halogen or trifluoromethyl; X is a linear or branched alkylen radical containing between 2 and 5 carbon atems which is unsubstituted or substituted by an alkoxy group and their racemates, enantiomers and diastereoisomers and addition salts thereof with a pharmaceutically acceptable acid. The novel compounds exhibit calcium antagonistic activity.

  描述了式(I)的 1,4-二氢吡啶-3,5-二羧酸碱式酯。 其中 R' 是含有 1-5 个碳原子的直链或支链烷基，未被取代或被烷氧基取代；R2 是苯基或硝基苯基；R3 是苯基、被一至三个基团取代的苯基，这些基团选自(C1-4)烷基、(C1-4)烷氧基、氟基、氯基、溴基、硝基、氰基、碳(C1-4)烷氧基、三氟甲基、羟基、氨基、单或双烷基氨基、单或双酰基氨基、巯基、S(O)n-烷基（n = 0、1 或 2）、(C1-C5)酰基、氨基甲酰基、脲基或 R3 是脲基、脲基或 R3 是含有一个或多个杂原子（N、0 或 S）的 5 或 6 位杂芳基单环基，如未取代的吡啶基、吡嗪基、嘧啶基、呋喃基、咪唑基、噻吩基、噻唑基、1,2,3-三唑基、1,2,4-三唑基，或由烷基、烷氧基、卤素或三氟甲基单取代、二取代或三取代的烷基；X 是含有 2 至 5 个碳原子的直链或支链烯基，未被烷氧基取代或被烷氧基取代，以及它们的外消旋体、对映体和非对映异构体及其与药学上可接受的酸的加成盐。这些新型化合物具有钙拮抗活性。
• Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid
  申请人：RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY

  公开号：EP0153016A2

  公开（公告）日：1985-08-28

  Compounds I (Ph = phenyl; Ar = 2 - nitrophenyl, 3-nitrophenyl, 2,3-dichlorphenyl or benzofurazan-4-yl; A = C2 - C6 alkylene; R = C1 - C6 alkyl optionally C1 - C6 alkoxy monosubstituted; R1 = H, OH or C1- C4 alkyl; R2 = H or CH3) have antihypertensive activity and are effective against coronary heart diseases. They are prepared starting from the aldehyde ArCHO and esters of acetoacetic acid and 3-amino-crotonic acid. Pharmaceutical preparations containing them are also described.

  化合物 I（Ph =苯基；Ar = 2-硝基苯基、3-硝基苯基、2,3-二氯苯基或苯并呋咱-4-基；A = C2 - C6 亚烷基；R = C1 - C6 烷基，可选 C1 - C6 烷氧基单取代；R1 = H、OH 或 C1 - C4 烷基；R2 = H 或 CH3）具有抗高血压活性，对冠心病有效。 它们是由醛 ArCHO 以及乙酰乙酸酯和 3-氨基巴豆酸酯制备而成。 此外，还介绍了含有这些化合物的药物制剂。
• DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS AND MEDICAL USES THEREOF
  申请人：Cosunter Pharmaceutical Company

  公开号：EP2251337B1

  公开（公告）日：2013-11-20
• Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0151006B1

  公开（公告）日：1991-08-28
• IWANAMI M.; SHIBANUMA T.; FUJIMOTO M.; KAWAI R.; TAMAZAWA K.; TAKENAKA T.+, CHEM. AND PHARM. BULL., 1979, 27, NO 6, 1426-1440
  作者：IWANAMI M.、 SHIBANUMA T.、 FUJIMOTO M.、 KAWAI R.、 TAMAZAWA K.、 TAKENAKA T.+

  DOI：——

  日期：——